Clearance of anti-double-stranded DNA antibodies: the natural immune complex clearance mechanism.
OBJECTIVE
To develop an in vitro model for investigating the mechanism by which autoantibodies in immune complexes (ICs) that are bound to primate erythrocytes via antigen-based heteropolymers (AHPs) are cleared from the circulation and localized to the liver.


METHODS
IgG anti-double-stranded DNA (anti-dsDNA) antibodies in ICs with dsDNA were bound to human erythrocytes via complement receptor 1 (CR1) either by opsonization with normal human serum as a complement source or through the use of an AHP, which consists of an anti-CR1 monoclonal antibody (mAb) that is chemically crosslinked with dsDNA. We performed parallel investigations of the mechanism of transfer of both types of erythrocyte-bound ICs to a monocytic cell line (U937). Erythrocytes with CR1-bound ICs were incubated with U937 cells under a variety of conditions, and subsequently, the levels of IgG anti-dsDNA, CR1, AHP, or C3b on both erythrocytes and U937 cells were measured by flow cytometry with appropriate fluorescently labeled probes.


RESULTS
In the presence of U937 cells, both the AHP-anti-dsDNA and C3b-opsonized ICs were rapidly removed from the erythrocytes; at 37 degrees C, more than half of the complexes were removed in 2 minutes. Monomeric mouse IgG2a mAb blocked the transfer of both types of complexes by 75%, suggesting that Fcgamma receptor type I (FcgammaRI) is the main phagocyte receptor responsible for the removal of ICs from erythrocytes. Levels of CR1 on the erythrocyte surface were reduced during transfer of the AHP-anti-dsDNA ICs, suggesting that transfer involves a concomitant removal of CR1, presumably by proteolysis.


CONCLUSIONS
Transfer of AHP-anti-dsDNA ICs from erythrocyte CR1 to model phagocytes occurs by a mechanism that is similar to the natural mechanism of IC clearance, involving recognition by FcgammaRI and removal of erythrocyte CR1 as key steps.
Craig
M L
ML
University of Virginia School of Medicine, Charlottesville, USA.
Bankovich
A J
AJ
McElhenny
J L
JL
Taylor
R P
RP
D000818:Animals; D000974:Antibodies, Antinuclear / Q000378:metabolism*; D000936:Antigen-Antibody Complex / Q000187:drug effects / Q000378:metabolism; D001327:Autoimmune Diseases / Q000378:metabolism; D004247:DNA / Q000276:immunology*; D004912:Erythrocytes / Q000737:chemistry / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology; D008180:Lupus Erythematosus, Systemic / Q000276:immunology; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors; D051379:Mice; D010586:Phagocytes / Q000276:immunology; D017463:Receptors, Complement 3b / Q000276:immunology; D020298:U937 Cells
D000974:Antibodies, Antinuclear; D000936:Antigen-Antibody Complex; D007074:Immunoglobulin G; D017463:Receptors, Complement 3b; D004247:DNA; D008666:Metalloendopeptidases